• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环色素上皮衍生因子缺乏是成骨不全症 VI 型的标志物。

Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI.

机构信息

Genetics Unit, Shriners Hospital for Children, and McGill University, Montréal, Quebec, Canada H3G 1A6.

出版信息

J Clin Endocrinol Metab. 2012 Aug;97(8):E1550-6. doi: 10.1210/jc.2012-1827. Epub 2012 Jun 5.

DOI:10.1210/jc.2012-1827
PMID:22669302
Abstract

BACKGROUND

Osteogenesis imperfecta (OI) type VI is a rare autosomal recessive bone fragility disorder that is caused by inactivating mutations in SERPINF1, the gene that encodes pigment-epithelium derived factor (PEDF). Determining PEDF serum levels might facilitate the diagnosis of OI type VI.

OBJECTIVE

The objective of the study was to assess whether lack of circulating PEDF is a specific marker of OI type VI and to evaluate whether PEDF serum levels are influenced by other metabolic bone diseases.

MATERIALS AND METHODS

Serum PEDF concentrations were measured in 12 patients with OI type VI (aged 2.7-31 yr) as well as in 96 children and adolescents with OI types I, III, and IV; in 26 young patients with hypophosphatemic rickets; and in 19 healthy controls.

RESULTS

Circulating PEDF was undetectable in all 12 patients with OI type VI but was measurable for the other 141 study participants. No significant differences in serum PEDF concentrations were found between the diagnostic groups other than OI type VI. Treatment with bisphosphonates (in OI types I, III, and IV) and with phosphate and calcitriol (in hypophosphatemic rickets) did not have a detectable influence on serum PEDF. In patients with OI types I, III, and IV, serum creatinine, body mass index z-score, and OI severity were significant predictors of PEDF serum levels.

CONCLUSION

Determining PEDF serum concentration helps to diagnose OI type VI but does not seem to provide information on the activity of bone turnover or mineralization.

摘要

背景

成骨不全症(OI)VI 型是一种罕见的常染色体隐性遗传性骨脆弱疾病,由编码色素上皮衍生因子(PEDF)的 SERPINF1 基因失活突变引起。测定 PEDF 血清水平可能有助于 OI VI 型的诊断。

目的

本研究旨在评估循环 PEDF 缺乏是否是 OI VI 型的特异性标志物,并评估 PEDF 血清水平是否受其他代谢性骨病的影响。

材料和方法

测定了 12 例 OI VI 型(年龄 2.7-31 岁)、96 例 OI I、III、IV 型儿童和青少年、26 例低磷血症性佝偻病和 19 例健康对照者的血清 PEDF 浓度。

结果

12 例 OI VI 型患者的血清 PEDF 均无法检测到,而其他 141 例研究参与者的血清 PEDF 均可检测到。除 OI VI 型外,各诊断组之间的血清 PEDF 浓度无显著差异。用双膦酸盐(OI I、III、IV 型)、磷酸盐和骨化三醇(低磷血症性佝偻病)治疗对血清 PEDF 无明显影响。在 OI I、III、IV 型患者中,血清肌酐、体重指数 z 评分和 OI 严重程度是 PEDF 血清水平的显著预测因素。

结论

测定 PEDF 血清浓度有助于诊断 OI VI 型,但似乎不能提供骨转换或矿化活性的信息。

相似文献

1
Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI.循环色素上皮衍生因子缺乏是成骨不全症 VI 型的标志物。
J Clin Endocrinol Metab. 2012 Aug;97(8):E1550-6. doi: 10.1210/jc.2012-1827. Epub 2012 Jun 5.
2
Extremely low level of serum pigment epithelium-derived factor is a special biomarker of Chinese osteogenesis imperfecta patients with SERPINF1 mutations.血清色素上皮衍生因子极低水平是中国成骨不全症 SERPINF1 突变患者的特殊生物标志物。
Clin Chim Acta. 2018 Mar;478:216-221. doi: 10.1016/j.cca.2017.10.032. Epub 2017 Nov 6.
3
Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice.恢复丝氨酸蛋白酶抑制剂F1(SERPINF1)的血清水平并不能纠正丝氨酸蛋白酶抑制剂F1基因敲除小鼠的骨骼表型。
Mol Genet Metab. 2016 Mar;117(3):378-82. doi: 10.1016/j.ymgme.2015.11.015. Epub 2015 Dec 2.
4
Novel Mutations in SERPINF1 Result in Rare Osteogenesis Imperfecta Type VI.丝氨酸蛋白酶抑制剂F1(SERPINF1)的新突变导致罕见的VI型成骨不全症。
Calcif Tissue Int. 2017 Jan;100(1):55-66. doi: 10.1007/s00223-016-0201-z. Epub 2016 Oct 28.
5
Pigment epithelium-derived factor restoration increases bone mass and improves bone plasticity in a model of osteogenesis imperfecta type VI via Wnt3a blockade.色素上皮衍生因子恢复通过Wnt3a阻断增加VI型成骨不全模型中的骨量并改善骨可塑性。
FASEB J. 2016 Aug;30(8):2837-48. doi: 10.1096/fj.201500027R. Epub 2016 Apr 28.
6
Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.加拿大北部人群中的VI型成骨不全症。
Calcif Tissue Int. 2016 Jun;98(6):566-72. doi: 10.1007/s00223-016-0110-1. Epub 2016 Jan 27.
7
Normal bone density and fat mass in heterozygous SERPINF1 mutation carriers.杂合子 SERPINF1 突变携带者的正常骨密度和脂肪量。
J Clin Endocrinol Metab. 2014 Nov;99(11):E2446-50. doi: 10.1210/jc.2014-2505. Epub 2014 Aug 15.
8
Antagonism Between PEDF and TGF-β Contributes to Type VI Osteogenesis Imperfecta Bone and Vascular Pathogenesis.色素上皮衍生因子(PEDF)与转化生长因子-β(TGF-β)之间的拮抗作用导致VI型成骨不全症的骨骼和血管发病机制。
J Bone Miner Res. 2022 May;37(5):925-937. doi: 10.1002/jbmr.4540. Epub 2022 Apr 13.
9
The effect of SERPINF1 in-frame mutations in osteogenesis imperfecta type VI.丝氨酸蛋白酶抑制剂F1(SERPINF1)框内突变在VI型成骨不全症中的作用。
Bone. 2015 Jul;76:115-20. doi: 10.1016/j.bone.2015.04.008. Epub 2015 Apr 11.
10
A co-occurrence of osteogenesis imperfecta type VI and cystinosis.VI 型成骨不全症与胱氨酸贮积症并存。
Am J Med Genet A. 2012 Jun;158A(6):1422-6. doi: 10.1002/ajmg.a.35319. Epub 2012 Apr 23.

引用本文的文献

1
Update on the Genetics of Osteogenesis Imperfecta.成骨不全症遗传学的最新进展。
Calcif Tissue Int. 2024 Dec;115(6):891-914. doi: 10.1007/s00223-024-01266-5. Epub 2024 Aug 11.
2
Molecular Genetic Diagnosis with Targeted Next Generation Sequencing in a Cohort of Turkish Osteogenesis Imperfecta Patients and their Genotype-phenotype Correlation.土耳其成骨不全患者队列中靶向新一代测序的分子遗传学诊断及其基因型-表型相关性
J Clin Res Pediatr Endocrinol. 2024 Dec 4;16(4):431-442. doi: 10.4274/jcrpe.galenos.2024.2022-12-8. Epub 2024 Jun 3.
3
gene variants causing late-onset progressive deforming osteogenesis imperfecta - A study of 18 patients from India.
导致迟发性进行性变形性成骨不全的基因变异——对18名印度患者的研究
Bone Rep. 2023 May 26;18:101690. doi: 10.1016/j.bonr.2023.101690. eCollection 2023 Jun.
4
Antagonism Between PEDF and TGF-β Contributes to Type VI Osteogenesis Imperfecta Bone and Vascular Pathogenesis.色素上皮衍生因子(PEDF)与转化生长因子-β(TGF-β)之间的拮抗作用导致VI型成骨不全症的骨骼和血管发病机制。
J Bone Miner Res. 2022 May;37(5):925-937. doi: 10.1002/jbmr.4540. Epub 2022 Apr 13.
5
PEDF deficiency increases the susceptibility of rd10 mice to retinal degeneration.PEDF 缺乏会增加 rd10 小鼠对视网膜变性的易感性。
Exp Eye Res. 2020 Sep;198:108121. doi: 10.1016/j.exer.2020.108121. Epub 2020 Jul 25.
6
Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.骨生物学:成骨不全症及相关罕见脆弱综合征的启示。
FEBS J. 2019 Aug;286(15):3033-3056. doi: 10.1111/febs.14963. Epub 2019 Jul 5.
7
Whole-Exome Sequencing Identifies an Intronic Cryptic Splice Site in Causing Osteogenesis Imperfecta Type VI.全外显子组测序鉴定出导致VI型成骨不全症的一个内含子隐蔽剪接位点。
JBMR Plus. 2018 Apr 16;2(4):235-239. doi: 10.1002/jbm4.10044. eCollection 2018 Jul.
8
The genetic implication of scoliosis in osteogenesis imperfecta: a review.成骨不全症中脊柱侧弯的遗传学意义:综述
J Spine Surg. 2017 Dec;3(4):666-678. doi: 10.21037/jss.2017.10.01.
9
Long-term follow-up in osteogenesis imperfecta type VI.成骨不全症 VI 型的长期随访。
Osteoporos Int. 2017 Oct;28(10):2975-2983. doi: 10.1007/s00198-017-4141-x. Epub 2017 Jul 9.
10
Pharmacological and biological therapeutic strategies for osteogenesis imperfecta.成骨不全症的药理和生物治疗策略。
Am J Med Genet C Semin Med Genet. 2016 Dec;172(4):367-383. doi: 10.1002/ajmg.c.31532. Epub 2016 Nov 3.